<< Back to News

KEYTRUDA Receives New FDA Approval

Merck is pleased to announce that KEYTRUDA, in combination with axitinib, has been approved by the FDA for the first-line treatment of patients with advanced renal cell carcinoma (RCC).

·    PD-L1 diagnostic testing is not required prior to initiating treatment with KEYTRUDA in these patients

Before prescribing KEYTRUDA® (pembrolizumab), please read the Prescribing Information.

The Medication Guide also is available.

Read the entire Press Release Here